An interventional study of Radiofrequency treatment in Infected Pilonidal Sinus, sponsored by CHI MONT DE MARSAN ET PAYS DES SOURCES. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-27.
Sponsored by CHI MONT DE MARSAN ET PAYS DES SOURCES · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Patient Satisfaction with a site in France — 16 open to participants now, 18 under way, none of them phase 3. Patient Satisfaction · France.
Among the 43 studies in Patient Satisfaction with a site in France, this one is the 15th largest by planned enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2026, is one of 17 with no phase, reaches primary completion later than 9 of the 17 other live ones, and was the 37th registered.
882 studies on the registry are indexed under Patient Satisfaction; 205 are open to participants now.
Browse Patient Satisfaction studies →16 of the 43 studies in Patient Satisfaction with a site in France are open now. Recruiting first, the newest first:
Suisselle · Sites in France
Ages 35+ · Healthy volunteers
University Hospital, Angers · Sites in France
Ages 18+
Centre Hospitalier de Martigues · Sites in France
Ages 18+
Centre Hospitalier Intercommunal Creteil · Sites in France
Ages 18+ · Women only
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–60 · Women only
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 102 Patient Satisfaction studies recruiting now, 63 (62%) set no upper age limit and 31 (30%) stop at 75 or younger; 14 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 96 across 627 interventional studies indexed under Patient Satisfaction.
Median enrollment 132 across the 18 interventional studies, 150 across the 25 observational. Of the 19 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 43 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with CHI MONT DE MARSAN ET PAYS DES SOURCES as lead sponsor.
CHI MONT DE MARSAN ET PAYS DES SOURCES has 1 study filed under Patient Satisfaction — fewer than ten, so there is no comparison to draw.
8 of the studies in Patient Satisfaction with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07668050University Hospital, Clermont-FerrandA Study of the Impact of a Virtual Reality Medical Device (HypnoVR® Headset) on Anxiety and Pain in Interventional Radiology. | 2026-12 |
| NCT07557589CHI MONT DE MARSAN ET PAYS DES SOURCESRadiofrequency Treatment for Pilonidal Disease : Clinical Investigation on Safety of Use, Efficacy and Patient Satisfaction at 6 Months | 2027-01 |
| NCT06100978Versailles HospitalPatient-reported Outcome and Patient-reported Experience After Status Epilepticus | 2027-03-25 |
| NCT07721350Hospices Civils de LyonProspective Evaluation of Subcutaneous Administration of Daratumumab by the FreedomEDGE® Infusion System | 2027-05 |
| NCT07146659Centre Hospitalier Intercommunal CreteilComparison of Operative Hysteroscopy Performed in the Operating Room Versus Outpatient Settings | 2027-05-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 43 studies in Patient Satisfaction with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Infected pilonidal sinus is a common suppuration that occurs twice as often in men as in women, usually between the ages of 15 and 30. Clinical diagnosis is easy, whether the presentation is acute or chronic. Exeresis with a wound left open requiring secondary postoperative healing is the most widely practiced technique in France because its recurrence rate is the lowest, but it has the disadvantage of requiring daily or even twice-daily local nursing care, long healing, and a break in activity.
In order to limit the disadvantages of the open technique, "conservative" minimally invasive techniques have also recently been developed in response to strong patient demand: such as endoscopic treatment (EPSIT = Endoscopic Pilonidal Sinus Treatment, or VAAPS = Video-Assisted Ablation of Pilonidal Sinus), or the SiLaT (Sinus Laser Therapy) laser.
More recently, radiofrequency has emerged as a new technique in the treatment of hemorrhoidal pathology according to the Rafaelo procedure as well as the Fistura procedure for anal fistulas. The principle of the treatment is similar to that of the laser, based on radio frequency thermocoagulation using very high frequency electromagnetic waves (4MHz), similar to the principle of microwaves. However, its use in the infected pilonidal sinus has not yet been described. The fibers used in anal fistulas are perfectly adapted to the treatment of the pilonidal sinus. In addition, and in contrast to the laser, several fiber diameters are available depending on the size of the fistula path(s). For example, the large diameters of 9 Fr seem to be more adapted to the deep and wide cavities of the pilonidal sinuses than those of the SiLaT, which has a single fiber diameter. The investigators can therefore think that this type of fibers could allow a more efficient destruction of the granulation tissues and a better docking of the cavity walls.
According to published studies in the treatment of anal fistulas, the safety profile of this treatment is perfectly reassuring since the penetrance of the energy released does not exceed 3 mm in depth.
The aim of this study is to evaluate the radiofrequency treatment according to the Fistura® procedure, by mesure its safety, efficacy and patient satisfaction on a series of consecutive patients treated for infected sinus pilonidal.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Radiofrequency using the Fistura procedure for treatment of infected pilonidal sinus
Device: Radiofrequency treatment
Radiofrequency using the Fistura procedure for treatment of infected pilonidal sinus
Evaluation of radiofrequency treatment safety
Incidence rate of at least one complication of the radiofrequency treatment : incidence rate of of haemorrhagic complication, incidence rate of acute urinary retention and incidence rate of others complications such as post radiofrequency treatment abcess, haematoma, localized infection.
Time frame: Within 15days after the radiofrequency treatment
Evaluation of radiofrequency treatment safety
Incidence rate of of haemorrhagic complication after the radiofrequency treatment
Time frame: Within 15days after the radiofrequency treatment
Evaluation of radiofrequency treatment safety
Incidence rate of acute urinary retention after the radiofrequency treatment
Time frame: Within 15days after the radiofrequency treatment
Evaluation of radiofrequency treatment safety
Incidence rate of others complications such as post radiofrequency treatment abcess, haematoma, localized infection.
Time frame: Within 15days after the radiofrequency treatment
Evaluation of post radiofrequency pain
Patient will be asked daily to evaluate post surgery pain using a Numerical Rating Scale (NRS). Patients will be asked to circle the number between 0 and 10 that fits best to their pain intensity. Zero represents 'no pain at all' whereas10 represents 'the worst pain ever possible'.
Time frame: Within 15days after the radiofrequency treatment
Evaluation of radiofrequency treatment efficiency
During the last patient visit, a clinical evaluation will be performed during which closure of all existing fistula external opening will be assessed (Yes or No), as well as the absence or presence of abcess and new external opening (Yes or no) . The patient will be asked to evaluate the presence or absence of pain (yes or no) The Treatment will be evaluated as efficient if there is closure of all fistula external opening AND absence of pain AND absence of abscess or new external opening.
Time frame: 6 months after the radiofrequency treatment
Length of the medical leave after the radiofrequency treatment
Record of number of medical leave days prescribed after the radiofrequency treatment Record of number of day after the radiofrequency treatmenty necessary before returning to normal activity.
Time frame: Within 6 months after the radiofrequency treatment
Measurement of patient satisfaction after the radiofrequency treatment
Each patient will evaluate their satisfaction regarding their radiofrequency treatment using a visual 5 point scale ranking from "very unsatified" to "very satisfied"
Time frame: At 1 mont and 6 months after the radiofrequency treatment
Plan to share: No
Started Apr 2026 (actual). Primary completion is estimated for Jan 2027, 9 months after the start.
Of 368 non-industry interventional studies with no phase under Patient Satisfaction, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 9 months is below that.
Counting every sponsor, half of 370 studies reached it within 12 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.